Annals of Clinical Biochemistry > Volume 44, Number 6 > Pp. 563-565

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leino, A. Articles by Loo, B.-M. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Short Reports

Comparison of three commercial tests for buprenorphine screening in urine

Aila Leino and Britt-Marie Loo

TYKSLAB Laboratory, Hospital District of Southwest Finland; Department of Clinical Chemistry, Turku University Central Hospital, Kiinamyllynkatu, Turku, Finland; The Joint Clinical Biochemistry Laboratory of University of Turku, Turku University Central Hospital and Wallac Ltd, Kiinamyllynkatu 4-8, Turku, Finland; TYKSLAB Laboratory, Hospital District of Southwest Finland

Background: Rapid and sensitive tests for detecting buprenorphine and its metabolites for drug-screening situations have been long awaited. From the tests available, we have evaluated two on-site drugs-of-abuse testing devices using competitive binding immunoassays and one homogeneous enzyme immunoassay measured on an automated analyser.

Methods: A total of 49 urine specimens were tested using three different kits. Two were point-of-care devices, a cassette test, QuikPac II OneStep Buprenorphine Test, and a strip test, QuikStrip OneStep Buprenorphine Test. The other was the CEDIA^® Buprenorphine Assay performed on a Roche Modular P analyser. The confirmation analyses were performed using liquid chromatography-mass spectrometry.

Results: The sensitivities of the three methods ranged from 88% to 100% and specificities from 91% to 100%. All three kits, especially the cassette and strip devices differed markedly from each other with respect to interpretation of the test result and to clarity of the test performance. Increasing the read time of the QuikStrip device from 5 to 30 min resulted in an increase in false-negative test results.

Conclusions: Our results indicate that special care should be taken when selecting immunology-based point-of-care methods for measurement of buprenorphine.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Twigger, E. Fox, and K. Allen Measurement of buprenorphine in urine: immunoassay versus LC-MS/MS Ann Clin Biochem, May 1, 2008; 45(3): 339 - 339. [Full Text] [PDF]